Surface Immunogenic Protein of Streptococcus Group B is an Agonist of Toll-Like Receptors 2 and 4 and a Potential Immune Adjuvant

Simple item page
dc.contributor.authorDíaz Dinamarca, Diego A.
dc.contributor.authorManzo, Ricardo A.
dc.contributor.authorSoto, Daniel A.
dc.contributor.authorAvendaño Valenzuela, María José
dc.contributor.authorBastías, Diego N.
dc.contributor.authorEscobar, Daniel F.
dc.contributor.authorSoto, Paulina I
dc.contributor.authorVásquez Sáez., Valeria
dc.contributor.authorCarrión, Flavio
dc.contributor.authorPizarro Ortega, Magdalena S.
dc.contributor.authorWilson Moya, Christian
dc.contributor.authorBerríos, Julio
dc.contributor.authorWilson Moya, Christian A.M.
dc.contributor.authorKalergis, Alexis M.
dc.contributor.authorVásquez, Abel E.
dc.date.accessioned2021-08-13T18:08:17Z
dc.date.available2021-08-13T18:08:17Z
dc.date.issued2020
dc.description.abstractVaccine-induced protection against pathogens, especially subunit-based vaccines, are related to antigen properties but mainly in their ability to stimulate the immune system by the use of an adjuvant. Modern vaccines are formulated with a high level of antigen purity, where an efficient adjuvant is necessary. In this context, the use of protein Toll-Like Receptor (TLR) agonists as vaccine adjuvants has been highlighted because of their optimal immunogenicity and minimal toxicity. The Surface Immunogenic Protein (SIP) from Group B Streptococcus (GBS) has gained importance as a new potential protein-based vaccine. Recently, we reported that recombinant SIP (rSIP) expressed by E. coli and purified by High Performance Liquid Chromatography (HPLC) alone induces a protective humoral immune response. In this study, we present the immunomodulatory properties of rSIP as a protein-based adjuvant, as an agonist of TLR. To this end, we showed that C57BL/6 bone marrow-derived dendritic cells pulsed by rSIP resulted in enhanced CD40, CD80, CD86, and Major Histocompatibility Complex (MHC) class II as well as increased secretion proinflammatory cytokines Interleukin (IL)-6, Interferon (IFN)-γ, Tumor Necrosis Factor (TNF)-α, and IL-10. Next, we investigated the in vivo effect of rSIP in the absence or presence of ovalbumin (OVA) on antigen-specific antibody secretion in C57BL/6 mice. Immunization with rSIP plus OVA showed that anti-OVA IgG2a and IgG1a increased significantly compared with OVA alone in C57BL/6 mice. Also, the immunization of rSIP plus OVA generates increased serum cytokines levels characterized by IL-12p70, IL-10, IL-4, and IFN-γ. Interestingly, we observed that rSIP stimulate Toll Like Receptor (TLR)2 and TLR4, individually expressed by Human embryonic kidney (HEK) 293-derived TLR reporter cells. These findings suggest that rSIP is a new potential protein TLR agonist adjuvant and may be employed in the development of new vaccines.es
dc.identifier.citationVaccines, 2020, vol.8(1), 29es
dc.identifier.urihttps://doi.org/10.3390/vaccines8010029es
dc.identifier.urihttp://hdl.handle.net/11447/4305
dc.language.isoenes
dc.subjectSurface immunogenic proteines
dc.subjectGroup B Streptococcuses
dc.subjectTRL2 and TLR4 agonistes
dc.subjectAdjuvant proteines
dc.titleSurface Immunogenic Protein of Streptococcus Group B is an Agonist of Toll-Like Receptors 2 and 4 and a Potential Immune Adjuvantes
dc.typeArticlees

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
vaccines-08-00029.pdf
Size:
1.33 MB
Format:
Adobe Portable Document Format
Description:
Texto completo
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services